AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$ALEC

Alector, Inc.

Price · $ALECvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ALEC in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $ALEC in the last 30 days.

Top stories · $ALECMore →
MAY 7·Stock TitanLow

Alector (NASDAQ: ALEC) Q1 2026 results, trial halt and ABC focus

Alector (NASDAQ: ALEC) reported its Q1 2026 financial results, revealing a narrowed net loss of $22.9 million and a strategic pivot towards its Alector Brain Carrier (ABC) platform. This shift follows the discontinuation of its Phase 2 Alzheimer's trial for nivisnebart due to a futility analysis. The company maintains a cash runway expected to fund operations through at least 2027, focusing on advancing multiple preclinical ABC-enabled programs for neurodegenerative diseases.

MAR 14·Stock Titan

Alector (ALEC) CEO awarded 116,246 RSUs, boosts direct share stake

Alector, Inc. CEO Arnon Rosenthal was granted 116,246 restricted stock units (RSUs) on March 13, 2026, as equity compensation. These RSUs, which have no cash cost, will vest in two equal installments on September 1, 2026, and March 1, 2027. This grant increases his direct ownership to 2,454,422 common shares, in addition to indirect holdings through family trusts.

DEC 12·GuruFocus

Alector (ALEC) Appoints Neil Berkley as CFO

Alector (ALEC) has appointed Neil Berkley as Chief Financial Officer, effective December 10, 2025, while he will also retain his responsibilities as Chief Business Officer. The biotechnology company, which focuses on neurodegenerative therapies, faces significant financial challenges including negative margins and declining revenue growth. Despite a stable liquidity position, an Altman Z-Score of -3.61 indicates potential bankruptcy risk, and recent insider activity shows substantial selling with no buying.

News on $ALEC

All news →